Yamaue H, Tanimura H, Tsunoda T, Iwahashi M, Tani M, Inoue M, Tamai M
Department of Gastroenterological Surgery, Wakayama Medical College.
Nihon Gan Chiryo Gakkai Shi. 1990 May 20;25(5):978-89.
The tumor-infiltrating lymphocytes (TIL) were cultured with interleukin 2 (IL-2) to induce the cytotoxic T lymphocytes possessing autologous tumor-killing activity from 21 cancer patients (11 with solid tumor and 10 with malignant peritoneal or pleural effusions), and transferred into 7 patients as IL-2-activated TIL adoptively. The clinical application of activated TIL by adoptive transfer could result the complete regression of malignant pleural effusions in a patient with pancreatic cancer, and the nearly complete regression of malignant ascites in a patient with gastric cancer. The autologous tumor cells were isolated at the purity of more than 90% by Ficoll-Hypaque and Percoll discontinuous gradients, and then the TIL were cultured with IL-2 until 4 weeks. The optimal concentration of IL-2 was 1,500 IU/ml to obtain maximum proliferation and autologous tumor killing activity. The cytotoxic activities of activated TIL at 3 weeks-incubation was 72 +/- 15, 42 +/- 26, 27 +/- 21 and 22 +/- 15% against K562, Daudi, KATO-III and autologous tumor, respectively. By negative selection method, it was clarified that the killer cells recognizing autologous tumor consisted of CD4 or CD8 positive T lymphocyte in 43% of patients. The CD8 positive cells and CD56 positive cells increased, the CD4 positive cells and CD16 positive cells decreased by flow cytometry. The activated TIL could lyse not only cultured tumor cell lines, also other autologous tumor cells. The CD56+ cells were isolated by the Panning method, these cells could not lyse autologous tumor cells. Thus, it was indicated that the cytotoxic T lymphocytes recognizing autologous tumor could be generated from TIL and the adoptive immunotherapy of activated TIL was effective in cancer therapy.
从21例癌症患者(11例实体瘤患者和10例恶性腹腔或胸腔积液患者)中获取肿瘤浸润淋巴细胞(TIL),用白细胞介素2(IL-2)进行培养,以诱导出具有自体肿瘤杀伤活性的细胞毒性T淋巴细胞,并将其作为IL-2激活的TIL过继性转移至7例患者体内。过继性转移激活的TIL的临床应用可使1例胰腺癌患者的恶性胸腔积液完全消退,1例胃癌患者的恶性腹水几乎完全消退。通过Ficoll-Hypaque和Percoll不连续梯度法分离出纯度超过90%的自体肿瘤细胞,然后将TIL与IL-2一起培养4周。获得最大增殖和自体肿瘤杀伤活性的IL-2最佳浓度为1500 IU/ml。培养3周时,激活的TIL对K562、Daudi、KATO-III和自体肿瘤的细胞毒性活性分别为72±15%、42±26%、27±21%和22±15%。通过阴性选择法明确,43%的患者中识别自体肿瘤的杀伤细胞由CD4或CD8阳性T淋巴细胞组成。通过流式细胞术检测发现,CD8阳性细胞和CD56阳性细胞增加,CD4阳性细胞和CD16阳性细胞减少。激活的TIL不仅能裂解培养的肿瘤细胞系,还能裂解其他自体肿瘤细胞。通过淘选法分离出CD56+细胞,这些细胞不能裂解自体肿瘤细胞。因此,表明可从TIL产生识别自体肿瘤的细胞毒性T淋巴细胞,激活的TIL过继性免疫疗法在癌症治疗中是有效的。